Vivodyne co-founders (L-R): CEO Andrei Georgescu and CSO Dan Huh

Khosla Ven­tures leads $38M seed round for organoid start­up Vivo­dyne

Khosla Ven­tures is lead­ing a seed round for a new biotech that aims to use ar­ti­fi­cial in­tel­li­gence to jump in­to the world of organoids.

Vivo­dyne an­nounced the $38 mil­lion seed fi­nanc­ing Wednes­day morn­ing, tout­ing its plat­form’s abil­i­ty to pro­duce hu­man-like tis­sue at every stage of drug de­vel­op­ment. The goal, CEO An­drei Georges­cu told End­points News, is to slash pre­clin­i­cal test­ing times by re­duc­ing the need for an­i­mal test­ing, and use the plat­form to learn how com­pounds will in­ter­act with hu­man cells at scale be­fore ac­tu­al­ly test­ing them in peo­ple.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.